Enzyme inhibition in drug development: Mechanisms and applications

Abstract

Enzyme inhibitors constitute over 40% of all marketed drugs. This isn't a coincidence-enzymes are attractive targets because they're specific, their mechanisms are well-characterized, and inhibiting them produces measurable biochemical effects. We analyzed 54 inhibitor compounds from recent drug discovery programs to understand how inhibition mechanism relates to clinical success. The compounds targeted five enzyme classes: kinases, proteases, phosphatases, dehydrogenases, and transferases. Kinase inhibitors showed the highest median efficacy at 78% maximum inhibition, while dehydrogenases proved more challenging at 58%. Competitive inhibitors demonstrated a clear relationship between IC₅₀ and selectivity (r²=0.73), with lower IC₅₀ values generally correlating with higher selectivity indices. Allosteric inhibitors showed the opposite pattern-they achieved high selectivity regardless of potency, which has obvious implications for drug design. The structure-activity analysis revealed molecular weight as a significant predictor of binding affinity, though the relationship wasn't straightforward. Compounds under 500 Da followed Lipinski's rules and generally performed better, but several exceptions existed. We observed that mechanism selection at project initiation strongly influenced downstream success rates. Projects starting with competitive inhibition had 67% success to candidate selection versus 41% for uncompetitive approaches. These data suggest that while all mechanisms can yield drugs, the path from hit to candidate varies substantially by approach.